泽布替尼、奥妥珠单抗和维奈克拉一线治疗伴TP53突变的套细胞淋巴瘤
这项多中心2期研究评估泽布替尼、奥妥珠单抗和维奈克拉(BOVen)方案一线治疗伴TP53突变的套细胞淋巴瘤,25例患者最佳总缓解率96%(24/25),完全缓解率88%(22/25),达到主要终点,耐受性良好。
要点
- BOVen方案在TP53突变套细胞淋巴瘤中最佳总缓解率96%(24/25),完全缓解率88%(22/25)。
- 中位随访28.2个月,2年无进展生存率72%、疾病特异性生存率91%、总生存率76%。
- 常见不良反应多为低级别:腹泻64%、中性粒细胞减少32%、输注相关反应24%。
核心结论
- BOVen方案耐受性良好,在TP53突变套细胞淋巴瘤中达到主要疗效终点,这些数据支持其使用和持续评估。
研究设计与样本
- 多中心2期研究,纳入25例未经治疗的伴TP53突变套细胞淋巴瘤患者。
- 患者先接受泽布替尼160 mg每日两次和奥妥珠单抗;奥妥珠单抗1000 mg于第1周期第1、8、15天及第2至8周期第1天给药。
- 2周期后加用维奈克拉,每周剂量递增至每日400 mg;24周期后若完全缓解且免疫测序检测微小残留病不可测(uMRD),则停止治疗。
- 主要终点为2年时无进展患者≥11例即达到。
主要发现
- 最佳总缓解率96%(24/25),完全缓解率88%(22/25)。
- 第13周期时,灵敏度1×10⁻⁵的uMRD频率为95%(18/19),灵敏度1×10⁻⁶的uMRD频率为84%(16/19)。
- 中位随访28.2个月,2年无进展生存率72%、疾病特异性生存率91%、总生存率76%。
- 常见副作用多为低级别:腹泻64%、中性粒细胞减少32%、输注相关反应24%。
关键数值与推荐
- 主要终点达到标准:2年时无进展患者≥11例。
- uMRD评估采用免疫测序法,灵敏度水平为1×10⁻⁵和1×10⁻⁶。
临床怎么用
- 原文结论指出这些数据支持BOVen的使用和持续评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TP53-mutant mantle cell lymphoma (MCL) is associated with poor survival outcomes with standard chemoimmunotherapy. We conducted a multicenter, phase 2 study of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in untreated patients with MCL with a TP53 mutation. Patients initially received 160 mg zanubrutinib twice daily and obinutuzumab. Obinutuzumab at a dose of 1000 mg was given on cycle 1 day 1, 8, and 15, and on day 1 of cycles 2 to 8. After 2 cycles, venetoclax was added with weekly dose ramp-up to 400 mg daily. After 24 cycles, if patients were in complete remission with undetectable minimal residual disease (uMRD) using an immunosequencing assay, treatment was discontinued. The primary end point was met if ≥11 patients were progression free at 2 years. The study included 25 patients with untreated MCL with a TP53 mutation. The best overall response rate was 96% (24/25) and the complete response rate was 88% (22/25). Frequency of uMRD at a sensitivity level of 1 × 10-5 and uMRD at a sensitivity level of 1 × 10-6 at cycle 13 was 95% (18/19) and 84% (16/19), respectively. With a median follow-up of 28.2 months, the 2-year progression-free, disease-specific, and overall survival were 72%, 91%, and 76%, respectively. Common side effects were generally low grade and included diarrhea (64%), neutropenia (32%), and infusion-related reactions (24%). BOVen was well tolerated and met its primary efficacy end point in TP53-mutant MCL. These data support its use and ongoing evaluation. This trial was registered at www.ClinicalTrials.gov as #NCT03824483.
引用
- Kumar A, Soumerai J, Abramson JS, et al. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. Blood. 2025. PMID: 39437708. doi:10.1182/blood.2024025563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。